TirzepaStar

About TirzepaStar

Tirzepatide/GLP-2T is a synthetic peptide widely classified as a GLP-2 dual agonist peptide, designed to activate both GLP-1 (glucagon-like peptide-1) and GLP-2-related incretin pathways via GIP receptor signaling. This dual-pathway activity differentiates tirzepatide from traditional GLP-1-only peptide therapies.

Activation of the GLP-1 receptor supports appetite suppression, delayed gastric emptying, enhanced satiety, and glucose-dependent insulin release. Concurrent GLP-2/GIP pathway activation contributes to improved insulin sensitivity, beta-cell responsiveness, nutrient utilization, and adipose tissue metabolism. Together, these mechanisms promote improved glycemic control, weight reduction, and metabolic efficiency.

Clinical research has extensively evaluated tirzepatide for type 2 diabetes, obesity, chronic weight management, insulin resistance, and cardiometabolic health. Phase 2 and Phase 3 studies have demonstrated significant improvements in HbA1c levels, fasting glucose, body weight, lipid profiles, and insulin sensitivity, often surpassing outcomes observed with GLP-1-only receptor agonists.

Tirzepatide’s molecular design is based on the native incretin peptide structure, with lipidation modifications that enhance stability and extend duration of action, allowing for once-weekly dosing. Tirzepatide has received regulatory approval under brand names such as Mounjaro and Zepbound, and continues to be studied for its broader effects on beta-cell health, metabolic signaling, and long-term GLP-1 and GLP-2 pathway modulation.

For research use only. Not for human or veterinary use, consumption, or therapeutic application.